Your session is about to expire
← Back to Search
Anti-inflammatory
AN2728 Topical Ointment, 2% for Atopic Dermatitis
Phase 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up aes: baseline (day 1) up to day 29, saes: baseline (day 1) up to day 36
Awards & highlights
Summary
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
Eligible Conditions
- Atopic Dermatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ aes: baseline (day 1) up to day 29, saes: baseline (day 1) up to day 36
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~aes: baseline (day 1) up to day 29, saes: baseline (day 1) up to day 36
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values at Day 29
Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29
Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)
+1 moreSecondary outcome measures
Change From Baseline in Signs of Atopic Dermatitis (AD) at Day 29
Percentage of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) at Day 29
Time to Achieve Treatment Success Based on Investigator's Static Global Assessment (ISGA)
Other outcome measures
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Day 29
Time to Improvement in Pruritus
Side effects data
From 2015 Phase 3 trial • 763 Patients • NCT0211876624%
Burning/Stinging: Mild
18%
Burning/Stinging: Moderate
8%
Burning/Stinging: Severe
6%
Application site pain
3%
Upper respiratory tract infection
3%
Pyrexia
2%
Vomiting
2%
Nasopharyngitis
2%
Nasal congestion
1%
Nausea
1%
Diarrhoea
1%
Pharyngitis
1%
Bronchitis
1%
Sinusitis
1%
Laceration
1%
Headache
1%
Oropharyngeal pain
1%
Dermatitis atopic
1%
Eczema
1%
Eczema infected
1%
Impetigo
1%
Application site pruritus
1%
Conjunctivitis
1%
Otitis media
1%
Cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
Crisaborole (AN2728) Ointment, 2 Percent
Crisaborole (AN2728) Ointment Vehicle
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AN2728 Topical Ointment, 2%Experimental Treatment1 Intervention
AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
Group II: Matching vehicle controlPlacebo Group1 Intervention
Matching vehicle control, applied twice daily for up to 28 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crisaborole
FDA approved
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,625 Previous Clinical Trials
14,283,431 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,518 Previous Clinical Trials
11,458,007 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger